Last reviewed · How we verify
TNP-2092 capsules
At a glance
| Generic name | TNP-2092 capsules |
|---|---|
| Also known as | Rifaquizinone, Rifaquizinone capsules, Placebo |
| Sponsor | TenNor Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Platelet count decreased
- Lipase increased
- neutrophil count decreased
- white blood cell count decreased
- Hypoalbuminaemia
- Blood fibrinogen decreased
- Urinary tract infection
- Anaemia
- White blood cell count increased
- Proteinuria
Key clinical trials
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules (PHASE1)
- PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia (PHASE1, PHASE2)
- A Phase 1 Study to Evaluate PK Profile of Multiple Oral Administrations of TNP-2092 Capsules in Healthy Subjects (PHASE1)
- The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNP-2092 capsules CI brief — competitive landscape report
- TNP-2092 capsules updates RSS · CI watch RSS
- TenNor Therapeutics Inc. portfolio CI